Beruflich Dokumente
Kultur Dokumente
Challenges and Opportunities for the Pharmaceutical Sector: Global and India
Intro to Pharma
Develops, produces, and markets drugs licensed for use as medications Are allowed to deal in generic and/or brand medications and medical devices Are subject to a variety of laws and regulations regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs. Often considered a defensive sector due to high level of regulation
Subsections
R&D Product Approval Patents and generics Marketing Mergers, acquisitions, and co-marketing of drugs (Business Development)
By 2020, the E7 (Brazil, China, India, Indonesia, Mexico, Russia and Turkey) could account for as much as one-fifth of global sales
Can we capitalize?
Current functioning not good enough Lack of productivity in the lab Spends far more on research and development (R&D) and produces far fewer new molecules than it did 20 years ago
5
Other Challenges
Increasing expenditure on sales and marketing Deteriorating financial performance Damaged reputation
At the start of the decade, many people thought that science would come to the industrys rescue and that molecular genetics would reveal numerous new biological targets But the human genome has proved otherwise It is no longer the speed at which scientific knowledge is advancing but the healthcare agenda of companies that is dictating how Pharma evolves
7
In India
The Indian pharmaceutical industry is the world's second-largest by volume India is currently ranked as the fourth largest pharmaceutical market in the Asia pacific region behind Japan, China and South Korea. The Indian pharma industry is expected to be ranked the 10th largest market of all the markets in the world by 2015.
In India (contd.)
The Indian pharmaceutical drug production accounts to around 10% of the global drug production The Indian pharma industry revenued US$ 16 billion in 2009 and is expected to reach US$ 40 billion by 2014 India ranks 3rd in Asia in clinical trails with around 350 clinical studies behind China and Japan. The Indian clinical trials market was estimated to be US$ 400 million in 2006
10
The Indian growing and aged population is expected to reach more than 1.4 billion by 2020
The population in India is even forecast to become larger than China (today 1.3 billion) after 2035, thus becoming the worlds most populous country with 1.6 billion Indians.
The percentage of people aged 65 and above will increase from 4.3% to 6.3% till 2020.
11
12
13
Global Challenges
Failing growth Organic R & D is increasingly being viewed as not delivering value Weaker New Drug pipeline and shorter periods of exclusivity
14
Global Challenges
Challenging times ahead of drug patent expirations Increasing operational costs Increasing regulatory pressures
15
Indian companies are setting up internal drug discovery programs as well as exploring partnerships with large & medium innovator companies
16
Global Issues
R&D Productive ?
Pharma must improve its R&D productivity, if it is to meet the worlds unmet medical needs and capitalise on the market opportunities now emerging
17
Global Issues
Global Issues
Price Control
Pharma will have to participate in the debate on healthcare funding and demonstrate the value of its products or risk coming under huge pressure to cut the prices of many massmarket medicines
19
20
21
Pharma Reputation
Unless Pharma improves its reputation, its political, commercial and clinical credibility will be eroded, with serious implications for its future success
22
In one recent analysis of 73 molecules that failed in Phase III, 50% of the compounds that failed did so because they could not be proved effective Compounds with novel mechanisms of action failed more than twice as often as those using established ones Such studies show that the industry is sinking large sums of money in developing molecules whose pharmacological impact it does not comprehend in sufficient detail beforehand
23
24
The Future??
25
26
Transgenic Production
27
28
References
www.wikipedia.com The Indian Pharma Industry:Danish Intl Business Development group Pharma 2020: The vision (PWC Sector Report and Analysis) Pharma 2020: Supplying the Future (PWC Sector Report and Analysis)
29
Thank You
30